K. Rocha

发表

JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.

L. Sokol, A. List, G. Caceres, 2010, Leukemia research.

Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression.

Sheng Wei, J. Maciejewski, J. Lancet, 2009 .

INHIBITION OF HISTONE DEACETYLASE 6 ACETYLATES AND DISRUPTS THE CHAPERONE FUNCTION OF HEAT SHOCK PROTEIN 90: A NOVEL BASIS OF ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS

J. Bradner, P. Atadja, K. Bhalla, 2005 .

Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

James Bradner, J. Bradner, P. Atadja, 2005, Journal of Biological Chemistry.

Gene Dosage of the Cell Cycle Regulatory Phosphatases Cdc25C and PP2A Determines Sensitivity to Lenalidomide in del(5q) MDS.

J. Byrd, Sheng Wei, J. Maciejewski, 2007 .

Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.

K. Bhalla, S. Boyapalle, B. Greedy, 2005, Cancer research.

Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2

H. Yamaguchi, K. Bhalla, Hong-Gang Wang, 2005, Clinical Cancer Research.

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

J. Byrd, Sheng Wei, J. Maciejewski, 2009, Proceedings of the National Academy of Sciences.

leukemia cells expressing human - deacetylase inhibitor LBH589 against Bcr-Abl Combined effects of novel tyrosine kinase inhibitor AMN107 and histone

P. Atadja, Jie Wu, K. Bhalla, 2013 .

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.

P. Atadja, Jie Wu, K. Bhalla, 2006, Blood.

Cotreatment with Vorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate–Sensitive or Imatinib Mesylate–Resistant Chronic Myelogenous Leukemia Cells

K. Bhalla, F. Lee, V. Richon, 2006, Clinical Cancer Research.

Cotreatment withVorinostat (Suberoylanilide Hydroxamic Acid) Enhances Activity of Dasatinib (BMS-354825) against Imatinib Mesylate^Sensitive or Imatinib Mesylate^Resistant Chronic Myelogenous Leukemia Cells

K. Bhalla, F. Lee, V. Richon, 2006 .

Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).

Sheng Wei, Jun-min Zhou, J. Tao, 2009 .

Erratum: A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide (Proceedings of the National Academy of Sciences of the United States of America (2009) 106:31 (12974-12979) DOI: 10.1073/pnas.0811267106)

J. Byrd, Sheng Wei, J. Maciejewski, 2013 .